Umeclidinium

Introduction Overview

Generic Name

umeclidinium

Brand Name

Incruse Ellipta

Dosage Form

inhalation powder (62.5 mcg/inhalation)

Drug Class

Anticholinergic bronchodilators

Pharmacokinetics

Absorption:
Umeclidinium bromide, when administered via inhalation powder, is rapidly absorbed into the systemic circulation primarily through the lungs. The inhaled dose results in localized delivery to the airway smooth muscle with minimal systemic exposure. In pharmacokinetic studies, peak plasma concentrations generally occur within 5 minutes post-inhalation, reflecting its rapid pulmonary absorption. Oral bioavailability is low due to poor gastrointestinal absorption and extensive first-pass metabolism when swallowed; however, this is clinically negligible because umeclidinium is intended for inhalation use. Factors such as inhalation technique and airway obstruction in COPD patients may influence pulmonary absorption.

Distribution:
Following systemic absorption, umeclidinium is distributed widely into the body tissues with a volume of distribution indicative of moderate tissue penetration. Plasma protein binding of umeclidinium is approximately 89%, primarily to albumin, which influences its distribution and elimination profile. The drug exhibits preferential affinity for muscarinic receptors in the bronchial smooth muscle, which explains its localized bronchial effects despite systemic distribution. Given its quaternary ammonium structure, its penetration through the blood-brain barrier is limited, minimizing central nervous system adverse effects.

Metabolism:
Umeclidinium undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, with CYP2D6 playing a significant role. It is metabolized into inactive metabolites through oxidative and hydrolytic pathways. The metabolism profile shows low potential for active metabolites contributing to therapeutic effects or toxicity. Genetic polymorphisms in CYP2D6 may affect individual metabolism, but these variations have not demonstrated significant clinical impact on efficacy or safety profiles.

Elimination:
The drug and its metabolites are eliminated predominantly via fecal excretion, accounting for approximately 58% of the administered dose, with less than 10% excreted in the urine. The terminal elimination half-life of umeclidinium after inhalation is about 11 hours, supporting once-daily dosing. Minimal renal clearance diminishes the need for renal dose adjustments, but hepatic impairment may alter elimination kinetics. The inhalation route limits systemic exposure, minimizing accumulation and systemic toxicity risks in normal dosing regimens.

Dosage Forms

Available Dosage Forms:
Umeclidinium is available as an inhalation powder delivered via a dry powder inhaler device (Ellipta). The marketed formulation contains 62.5 micrograms (0.0625 mg) of umeclidinium per inhalation.

Dosages for Adults and Adolescents:
The approved dosing regimen for adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, is one inhalation containing 62.5 mcg of umeclidinium once daily. The dose should not be repeated within 24 hours. The safety and efficacy of umeclidinium in patients younger than 18 years have not been established.

Specific Patient Populations:
No dose adjustments are generally required for elderly patients, patients with mild to moderate hepatic impairment, or those with renal impairment due to its low systemic exposure. However, caution is advised in patients with severe hepatic impairment as pharmacokinetic data are limited. Umeclidinium is contraindicated in individuals with known hypersensitivity to any component of the drug, including milk protein allergy due to excipient formulations. It is not approved for use in asthma patients or pediatric populations.

Mechanism Of Action

Umeclidinium acts as a long-acting muscarinic receptor antagonist (LAMA) by selectively inhibiting M3 muscarinic receptors located on bronchial smooth muscle. These receptors mediate acetylcholine-induced bronchoconstriction, which is a major pathophysiological component of COPD. By blocking these receptors, umeclidinium causes relaxation of airway smooth muscle, leading to sustained bronchodilation and improved airflow.

At the molecular level, umeclidinium competitively binds to the orthosteric site on muscarinic receptors, preventing acetylcholine from activating the G-protein coupled receptor signaling cascade. This inhibition decreases intracellular inositol triphosphate (IP3) levels and reduces calcium release from the sarcoplasmic reticulum in airway smooth muscle cells, preventing contraction.

In clinical contexts, the prolonged receptor binding affinity and slow dissociation rate of umeclidinium enable once-daily dosing with sustained bronchodilatory effects. Comparative studies show umeclidinium's bronchodilator efficacy to be similar or superior to other LAMAs such as tiotropium, with a favorable safety profile. Its selectivity for M3 over M2 receptors minimizes cardiac and salivary side effects often associated with anticholinergic therapy.

Research evidence from pivotal clinical trials demonstrates improvement in lung function measures such as forced expiratory volume in one second (FEV1), reduction in COPD exacerbations, and improved quality of life in patients treated with umeclidinium. The drug’s mechanism complements beta-2 agonists, providing additive bronchodilation when used in combination therapies.

Pharmacological Actions

Long-acting muscarinic antagonist bronchodilation via M3 receptor inhibition.
Relaxation of airway smooth muscle to improve airflow in COPD patients.
Reduction of acetylcholine-induced bronchoconstriction.
Selective blockade minimizes systemic anticholinergic side effects.
Sustained duration of action supporting once-daily dosing.
Improves spirometric parameters, including FEV1.
Decreases frequency and severity of COPD exacerbations.
Minimal central nervous system penetration reduces cognitive risk.
Complementary effects with beta-2 agonists for combination therapy.
Negligible anticholinergic effects on salivary and cardiac muscarinic receptors at therapeutic doses.
Inhibits muscarinic receptor-mediated mucus secretion, aiding airway clearance.
Demonstrated efficacy in maintenance therapy for chronic bronchitis and emphysema.

Therapeutic Or Clinical Uses

Maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
Management of symptoms in patients with chronic bronchitis associated with COPD.
Improvement of lung function in emphysema patients.
Reduction of COPD exacerbation frequency and severity.
Therapy adjunct to improve exercise tolerance in COPD patients.
Alternative bronchodilator for patients intolerant to beta-agonists.
In combination regimens with other bronchodilators for enhanced control.
Not indicated for acute bronchospasm or rescue therapy in COPD.
Treatment option for patients with COPD unable to tolerate inhaled corticosteroids.
Supports reduction of inhaled corticosteroid doses when combined appropriately.
Suitable for once-daily dosing regimen to improve patient adherence.
Not approved or recommended for treatment of asthma.

Side Or Adverse Effects

Upper respiratory tract infections presenting as cold-like symptoms including stuffy nose, sneezing, sore throat, and cough.
Cardiac arrhythmias such as fast or irregular heartbeats.
Bruising and skin discoloration.
Oral mucosa discomfort including mouth and tooth pain.
Musculoskeletal pain including muscle and joint aches.
Gastrointestinal disturbances such as stomach pain.
Altered or disturbed sense of taste.
Potential for allergic reactions manifesting as rash, hives, swelling, or breathing difficulties.
Ocular side effects including blurred vision, eye pain, redness, and visual disturbances such as halos or colored lights.
Urinary retention or difficult, painful urination, particularly in patients with prostate enlargement.
Dry mouth and throat irritation have been reported.
Rare but serious anticholinergic effects such as paradoxical bronchospasm.
Headache and dizziness in some patients.
Possible increase in intraocular pressure; caution in patients with glaucoma.
Rare hypersensitivity reactions including anaphylaxis.

Precautions

Should not be used in patients with a known hypersensitivity to umeclidinium or milk proteins.
Use cautiously in patients with narrow-angle glaucoma due to potential increased intraocular pressure.
Exercise caution in patients with prostatic hypertrophy or bladder neck obstruction to avoid urinary retention.
Not to be used as a rescue or acute bronchodilator for sudden bronchospasm episodes.
Use with caution in patients with significant cardiovascular disease due to possible tachyarrhythmias.
Advise patients on correct inhaler technique to ensure effective drug delivery.
Evaluate patients regularly for therapeutic efficacy and adverse effects.
Monitor elderly patients closely due to increased sensitivity to anticholinergic side effects.
Avoid concurrent use with other anticholinergic agents or bronchodilators unless prescribed.
Not recommended for use in pediatric patients under 18 years due to lack of safety data.
Pregnancy and breastfeeding use should be under medical supervision weighing risks versus benefits.
Use caution in patients with renal or hepatic impairment despite limited systemic absorption.
Alert patients regarding possible blurred vision or difficulty urinating and advise to report these effects promptly.
Avoid abrupt discontinuation without physician advice to maintain symptom control.
Instruct patients to store inhaler properly and discard according to manufacturer guidelines to maintain drug potency.

Warnings

Contraindicated in patients with hypersensitivity to umeclidinium or any of its components, including allergy to milk proteins present in the formulation.
Not suitable as a rescue inhaler for acute bronchospasm; patients should always have access to a fast-acting bronchodilator.
Prompt medical attention is required if breathing difficulties worsen or do not improve with treatment.
Potential for serious anticholinergic side effects including paradoxical bronchospasm.
Use with caution in patients with narrow-angle glaucoma or urinary retention.
Inhaler should be discarded 6 weeks after opening or when dose counter reaches zero to avoid diminished efficacy.
Avoid use in combination with other inhaled bronchodilators containing similar anticholinergic agents unless under medical supervision.
Patients should be warned against exceeding the once-daily dosing to minimize risk of overdose.
May cause cardiovascular effects such as tachyarrhythmia; monitor patients with underlying heart conditions.
May cause ocular complications; discontinue immediately if eye pain or vision changes occur.
Not approved for pediatric use; safety and efficacy in children not established.
Potential interactions with other anticholinergic drugs require vigilant clinical monitoring.
Risks of hypersensitivity reactions including anaphylaxis necessitate patient education on symptom identification.
Ensure patient understanding that improvement in symptoms may take several days after initiation.
Drug should be kept out of reach of children to prevent accidental ingestion or misuse.

Contraindication

Known hypersensitivity or allergy to umeclidinium bromide or any of its excipients.
Severe allergic reaction to milk proteins, as the formulation contains lactose excipients.
Not appropriate for treatment of asthma or acute bronchospasm.
Hypersensitivity to other anticholinergic agents requiring avoidance due to cross-reactivity risk.
Patients with acute respiratory illnesses that require different management.
Use is contraindicated if the patient requires immediate relief of bronchospasm symptoms.
Patients who have experienced angioedema attributable to inhaled anticholinergic drugs.
Avoid in patients with untreated narrow-angle glaucoma without proper medical supervision.
Contraindicated in patients with urinary retention disorders without appropriate management.

Drug Interactions

Concurrent use with other anticholinergic-containing inhalers (e.g., tiotropium, aclidinium, glycopyrrolate) may increase anticholinergic adverse effects.
Potential additive anticholinergic effects with systemic anticholinergic medications, increasing risk of dry mouth, constipation, urinary retention, and blurred vision.
May interact with tricyclic antidepressants and antipsychotics, enhancing anticholinergic side effects.
Coadministration with medications used for Parkinson's disease (e.g., levodopa) may require dose monitoring due to overlapping anticholinergic properties.
Cold and allergy over-the-counter medications containing antihistamines may potentiate anticholinergic side effects.
Interactions with medications used to treat depression, anxiety, or mood disorders require careful monitoring.
Agents used for overactive bladder may have additive effects, necessitating physician supervision.
No significant cytochrome P450-based interactions documented, but caution is advised with CYP2D6 inhibitors or inducers due to metabolism involvement.
Concomitant use with beta-agonists should be based on clinical judgment to avoid additive cardiovascular effects.
Use with caution alongside medications affecting gastrointestinal motility or secretion.
Potential interaction with drugs used for motion sickness or irritable bowel syndrome that have anticholinergic effects.
Patients should report use of herbal supplements or vitamins that may influence drug metabolism or anticholinergic burden.
Clinicians should evaluate all polypharmacy risks in elderly patients prescribed umeclidinium.
No documented clinically significant interactions with commonly prescribed antibiotics or anticoagulants.
Regular medication review is advised to identify and manage possible interactions.

Preparations Of The Drug

Incruse Ellipta inhalation powder device containing 62.5 mcg umeclidinium per inhalation.
Dry powder inhaler preloaded with approximately 30 doses per device.
Lactose as a carrier excipient; contraindicated in patients with milk protein allergy.
Single-dose inhaler designed for once-daily administration.
Packaged in a sealed foil tray to protect from moisture until initial use.
Disposable device that should be discarded 6 weeks after opening or when dose counter reaches zero.
No oral tablet, liquid, or injectable formulations commercially available.
Device includes dose counter window for monitoring remaining doses.
Instructions for Use leaflet included to educate proper inhaler technique.
Storage recommendations: room temperature, protected from moisture and heat.
Not suitable for modification or dismantling; cleaning procedures are not recommended.
Device designed for use in adult COPD patients only, with contraindications noted.
Compatible with standard COPD treatment protocols when combined with other inhaled therapies.
Manufactured under stringent regulatory standards ensuring consistent dosing and quality.
Patient education programs often accompany device dispensing to maximize therapeutic outcomes.